Endpoint and Assessment Support for Even the Most Challenging Trials

WCG offers comprehensive scale management and development services, including scale administration. We work with our network of test publishers, copyright holders, and scale authors to obtain permission and licensing agreements.

WCG also offers in-house translation and cultural adaptation services in 150+ languages to ensure your measures remain culturally and conceptually accurate.

100+

scales supported

150+

languages supported by our in-house translation team

WCG’s Proprietary Rater Scales

Desktop Patient Card

BAC

Our proprietary Brief Assessment of Cognition (BAC) is a user-friendly electronic cognitive assessment battery with improved sensitivity to impairment.

Video Play

VRFCAT

Our proprietary Virtual Reality Functional Capacity Assessment Tool (VRFCAT) integrates virtual reality into the assessment of functioning in clinical trials.

Virtual Meeting

SCoRS

Our proprietary Schizophrenia Cognition Rating Scale (SCoRS) is an interview-based clinical measure sensitive to treatment effects.

Mobile Three Sliders

SNAPSI

Our Simplified Negative and Positive Symptoms Interview facilitates quick and valid rating on the 6-item version of the Positive and Negative Syndrome Scale.

Additional supported clinical, cognitive, and functional
endpoints and assessments

  • ABAS-III- Adaptive Behavior Assessment System – 3rd Edition
  • ABC – Aberrant Behavior Checklist
  • ADAS-Cog- Alzheimer’s Disease Assessment Scale – Cognitive subscale
  • ADCS-ADL- Alzheimer’s Disease Cooperative Study Activities of Daily Living
  • ADCS CGIC- Alzheimer’s Disease Cooperative Study Clinician’s Global Impression of Change
  • ADHD-RS- ADHD Rating Scale
  • ADI-R – Autism Diagnostic Interview-Revised
  • ADOS-2 – Autism Diagnostic Observation Schedule-2
  • AIMS- Abnormal Involuntary Movement Scale
  • ALSFRS-R- ALS Functional Rating Scale-Revised
  • ANT- Attention Network Task
  • BAC*- Brief Assessment of Cognition
  • BAC-A*- Brief Assessment of Cognition in Affective Disorders
  • BACS*- Brief Assessment of Cognition in Schizophrenia
  • BARS- Barnes Akathisia Rating Scale
  • BET- Balloon Effort Test
  • BNT- Boston Naming Test
  • BP-CoRS*- Bipolar Cognition Rating Scale
  • BPRS- Brief Psychiatric Rating Scale
  • BSID- Bayley Scales of Infant and Toddler Development
  • BVMT-R- Brief Visuospatial Memory Test-Revised
  • C-SSRS- Columbia Suicide Severity Rating Scale
  • CAI- Cognitive Assessment Interview
  • CAINS- Clinical Assessment Interview for Negative Symptoms
  • CBCL- Child Behavior Checklist
  • CDR/CDR-SB- Clinical Dementia Rating Scale/Clinical Dementia Rating Sum of Boxes
  • CDSS- Calgary Depression Scale for Schizophrenia
  • CDT- Clock Drawing Test
  • CDR- Clinical Dementia Rating Scale
  • CERAD Battery- Consortium to Establish Registry for Alzheimer’s Disease Clinical & Neuropsychology Assessment
  • CFI- Cognitive Functioning Instrument
  • CGI-CogS- Clinical Global Impression of Cognition in Schizophrenia
  • CGI-C- Clinical Global Impression of Cognition
  • CGI-S/CGI-I- Clinical Global Impressions – Severity of Illness/Global Improvement
  • CIBIC+- Clinician’s Interview Based Impression of Change plus Caregiver Input
  • COWAT (FAS)- Controlled Oral Word Association Test
  • CPT- Continuous Performance Test
  • CVLT-II- California Verbal Learning Test – 2nd Edition
  • DCFS- Dementia Cognitive Fluctuations Scale
  • Digit Span
  • DSST- Digit Symbol Substitution Test
  • EDSS-NS– Neurostatus – Expanded Disability Status Scale
  • EQ-5D-5L- EuroQol – Five Dimensions
  • ESRS- Extrapyramidal Symptoms Rating Scale
  • ESS- Epworth Sleepiness Scale
  • FAQ- Functional Activities Questionnaire
  • FCSRT- Free and Cued Selective Reminding Test
  • Finger Tapping
  • FOGQ- Freezing of Gait Questionnaire
  • GDS- Geriatric Depression Scale
  • GOSE- Glasgow Outcome Scale
  • GRID-HAMD- GRID Hamilton Depression Rating Scale
  • Grooved Pegboard
  • HAM-A- Hamilton Anxiety Rating Scale
  • HAM-D- Hamilton Depression Rating Scale
  • HINE – Hammersmith Infant Neurological Examination
  • HVLT-R- Hopkins Verbal Learning Test – Revised
  • IQCODE- Informant Questionnaire on Cognitive Decline in the Elderly
  • KABC- Kaufman Assessment Battery for Children
  • LCLA- Low Contrast Letter Acuity
  • Lexical Fluency
  • LNS- Letter-Number Sequencing
  • LNS- Maryland Letter Number Span
  • MADRS- Montgomery-Åsberg Depression Rating Scale
  • MASC- Movie for the Assessment of Social Cognition
  • MCCB- MATRICS Consensus Cognitive Battery
  • MDS-UPDRS- Movement Disorder Society – Unified Parkinson’s Disease Rating Scale
  • MFIS-5- Modified Fatigue Impact Scale – 5 Item Version
  • MHY- Modified Hoehn & Yahr
  • MINI- Mini International Neuropsychiatric Interview
  • MiNT- Multilingual Naming Test
  • MMSE- Mini-Mental State Examination
  • MoCA- Montreal Cognitive Assessment
  • MSCEIT- Mayer-Salovey-Caruso Emotional Intelligence Test
  • MSCEIT-ME- Mayer-Salovey-Caruso Emotional Intelligence Test
  • MSIOA*- Multiple Sclerosis Individual Outcome Assessment
  • MSIS-29v2- Multiple Sclerosis Impact Scale -29 – Version 2
  • NAB Digit Span- Neuropsychological Assessment Battery Digit Span
  • NAB Mazes- Neuropsychological Assessment Battery Mazes
  • NAB Memory Modules- Neuropsychological Assessment Battery Modules
  • N-back
  • NMSS- Non-motor Symptom Scale
  • NMSQ- Non-motor Symptoms Questionnaire
  • NPI- Neuropsychiatric Inventory
  • NPI-Q- Neuropsychiatric Inventory – Questionnaire
  • NSA-16/NSA-4- Negative Symptoms Assessment- 16 items and 4 items
  • NSAA- North Star Ambulatory Assessment
  • NTB- Neuropsychological Test Battery
  • PACC Battery- Preclinical Alzheimer Cognitive Composite
  • PANSS- Positive and Negative Syndrome Scale
  • PAS- Parkinson’s Anxiety Scale
  • PD-CRS- Parkinson’s Disease – Cognitive Rating Scale
  • PD-CFRS- Parkinson’s Disease – Cognitive Function Rating Scale
  • PDMS-2 – Peabody Developmental Motor Scales
  • PDSS-2- Parkinson’s Disease Sleep Scale
  • PDQ-8- Parkinson’s Disease Questionnaire – 8
  • PedsQL- Pediatric Quality of Life Inventory
  • PGIC- Patient Global Impression of Change
  • PPQ- Parkinson’s Psychosis Questionnaire
  • PPT- Purdue Pegboard Test
  • PROMIS- Patient Reported Outcomes Measurement Information System
  • PSP- Personal and Social Performance Scale
  • Q-LES-Q-SF- Quality of Life Enjoyment and Satisfaction Questionaire – Short Form
  • QoL-AD- Quality of Life – Alzheimer’s Disease
  • QUIP-RS- Questionnaire for Impulsive-Compulsive Disorders in PD Rating Scale
  • RAVLT- Rey Auditory Verbal Learning Test
  • RBANS- Repeatable Battery for the Assessment of Neuropsychological Status
  • REY-AVLT- Rey Auditory Verbal Learning Test
  • RUD-lite- Resource Utilization in Dementia
  • SAPS-PD- Scale for the Assessment of Positive Symptoms for PD Psychosis
  • SAS- Simpson-Angus Scale
  • SCOPA- Scales for Outcomes of Parkinson’s Disease Cognition and Sleep
  • SCoRS- Schizophrenia Cognition Rating Scale
  • SDMT- Symbol Digit Modalities Test
  • SE-ADL- Schwab and England Activities of Daily Living Scale
  • Semantic Fluency
  • SF-36- 36-Item Short Form Health Survey
  • SFS- Social Functioning Scale
  • SIGH-D- Structured Interview Guide for the Hamilton Depression Inventory
  • SIGMA- Structured Interview Guide for Montgomery-Åsberg Depression Rating Scale
  • SIPS/SOPS- Structured Interview for Prodromal Syndromes/ Scale of Prodromal Syndromes
  • SLOF- Specific Levels of Functioning Scale
  • Symbol Coding
  • TMT A&B- Trail Making Test A and B
  • ToPF- Test of Premorbid Functioning
  • TOVA- Test of Variables of Attention
  • T25FW- Timed 25 Foot Walk
  • UDysRS- Unified Dyskinesia Rating Scale
  • UPSA- UCSD Performance-Based Skills Assessment (UPSA-2, UPSA-2-VIM, UPSA-2ER, UPSA-B)
  • VABS-II- Vineland Adaptive Behavior Scale: 2nd Edition
  • VABS-III- Vineland Adaptive Behavior Scale: 3rd Edition
  • vADAS-cog- Vascular Alzheimer’s Disease Assessment Scale – Cognitive Subscale
  • Verbal Fluency
  • VRFCAT*- Virtual Reality Functional Capacity Assessment Tool
  • WAIS III- Wechsler Adult Intelligence Scale – 3rd Edition
  • WASI-II- Wechsler Abbreviated Scale of Intelligence – 2nd Edition
  • WASI-IV- Wechsler Abbreviated Scale of Intelligence – 4th Edition
  • WCST-64- Wisconsin Card Sorting Test (Computerized and Card Versions)
  • WISC-III- Wechsler Intelligence Scale for Children
  • WMS-III/IV- Wechsler Memory Scale
  • WRAT III/IV- Wide Range Achievement Test
  • WTAR- Wechsler Test of Adult Reading
  • YGTSS- Yale Global Tic Severity Scale
  • YMRS- Young Mania Rating Scale
  • ZCI-AD- Zarit Caregiver Interview – Alzheimer’s Disease
  • 9-HPT- Nine Hole Peg Test

Learn more about WCG’s proprietary assessments

Brief Assessment of Cognition (BAC)

BAC is a user-friendly electronic cognitive assessment battery with improved sensitivity to impairment.

BAC is quick and easy to administer while preserving the human interaction of traditional neurocognitive testing that is necessary for impaired populations. The electronic BAC Assessment provides investigators with meaningful results while reducing rater and patient burden.

The tablet-based Brief Assessment of Cognition in Schizophrenia is a proprietary measure designed by WCG experts.

The BAC Measures Performance Across Multiple Cognitive Domains:

  • Verbal Memory
  • Processing Speed
  • Working Memory
  • Verbal Fluency
  • Motor Function
  • Executive Function

Key benefits of the BAC:

  • Scientifically validated
  • Large database of available normative data
  • Alternate forms for repeated testing
  • Automated response capture and scoring
  • High reliability and sensitivity to impairment
  • Available in multiple languages

The Virtual Reality Functional Capacity Assessment Tool (VRFCAT)

The VRFCAT is a tablet-based task that simulates key instrumental activities of daily living (iADLS) in a realistic and interactive virtual environment.

With demonstrated sensitivity to basic functional capacity deficits, the VRFCAT was developed to improve clinical trials by detecting functionally meaningful improvements in patients’ everyday lives.

The VRFCAT has numerous advantages over conventional assessments, and meets the highest psychometric and regulatory standards, with strong support from industry sponsors, NIH and FDA as a functional co-primary outcome measure.

The VRFCAT has officially been accepted into the FDA’s COA Qualification Program as a measure of functional capacity for schizophrenia treatment trials. This FDA program is intended to qualify drug development tools that can be relied on to have a specific interpretation and application in any drug development program and regulatory review. The FDA also awarded a grant to conduct further research on the VRFCAT.

Advantages of the VRFCAT:

  • Scientifically validated
  • Accurate, performance-based results
  • Integrated data capture
  • Alternate forms for repeated testing
  • Eases administrator burden
  • Well-tolerated by patients
  • Available in multiple languages and culturally adapted environments
  • Fast, responsive 24/7 technical support
  • FDA 21 CFR Part 11 Compliant

Schizophrenia Cognition Rating Scale (SCoRS)

The Schizophrenia Cognition Rating Scale (SCoRS) is a 20-item interview-based clinical assessment available on tablet or via pen-and-paper that evaluates cognitive deficits and the degree to which these deficits impair patients’ day-to-day functioning. It was originally developed in 2001 at Duke University Medical Center by Dr. Richard Keefe and is licensed through WCG. The SCoRS is used in registration-level clinical trials, academic research and in clinical settings.

The SCoRS contains questions about the patient’s ability to manage cognitively demanding, functionally relevant, everyday tasks such as conversations, watching television and using electronic devices.

The items were developed to assess the following cognitive domains:

  • Attention
  • Memory
  • Working Memory
  • Language Production
  • Reasoning
  • Problem Solving
  • Motor Skills
  • Social Cognition

As an interview-based assessment of cognition, the SCoRS meets the criteria established by the FDA-NIMH-MATRICS panel for co-primary outcome measures for cognitive enhancement trials in schizophrenia. Contact us today to learn more about the Schizophrenia Cognition Rating Scale.

Contact us to learn more or get started

Complete this form to contact our team about our endpoint and outcome services.